Share this:
July 28th, 2016

Mayo Clinic Studying Genomics of Antiplatelet Heart Medication

By Sharon Rosen

PharmacogenomicsAngioplasty offers lifesaving treatment without open heart surgery. But, it comes with risks. Researchers at the Center for Individualized Medicine are trying to determine if your individual genetic blue print can pinpoint drugs that reduce the risk of dangerous side effects.

The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient’s CYP2C19  genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.

TAILOR-PCI, which began in 2013 with study teams at 15 hospitals in the U.S., Canada and South Korea and plans to enroll 5,270 patients, just received an additional $7 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), to complete the study. Twenty nine medical centers are now participating with more to be added soon.

The randomized comparison of  Plavix (clopidogrel bisulfate)  and Brilinta (ticagrelor) was launched by Mayo Clinic Center for Individualized Medicine and the Department of Cardiovascular Diseases at Mayo Clinic in collaboration with the Peter Munk Cardiac Centre and the Applied Health Research Centre at the University of Toronto, Canada and Spartan Bioscience, Ottawa.

MSS_0001269758

Dr. Naveen Pereira

“The NHLBI grant is validation of the importance of the question that needs to be answered: Is pharmacogenomics useful in prescribing individualized anti-platelet therapy after PCI,” says Naveen Pereira, M.D., Mayo Clinic cardiologist and principal investigator of TAILOR-PCI. “This study will tell us whether this gene plays an important role in determining response to anti-platelet therapy after coronary interventions.”

Michael Farkouh, M.D., M.Sc., cardiologist from the Peter Munk Cardiac Centre and principal investigator, describes this large, simple trial as “a true multinational collaboration designed to best inform clinical practice.”

Yves Rosenberg, M.D., the NHLBI program officer for the study, and chief of the Atherothrombosis and Coronary Artery Disease Branch, added, “NHLBI is happy to support this important study, which we hope will contribute to the evidence needed to start delivering precision medicine in clinical settings. This trial could have global impact by potentially changing treatment recommendations for millions of individuals with coronary artery disease needing antiplatelet treatment after a percutaneous coronary intervention.”

The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the U.S. The current standard of care after angioplasty is to prescribe clopidogrel for one year.

“Today, we do this regardless of a person’s individual genotype, even though we have known for several years that variation in the CYP2C19 gene may diminish the benefit from the drug,” Dr. Pereira says. “What we don’t know — and why there is such confusion in the cardiovascular community — is whether these genetic differences affect long-term clinical outcomes.”

Antiplatelet medication reduces the risk of heart attack, unstable angina, stroke and cardiovascular death after stent placement by reducing the possibility of blood clots around the surgical site.

Clopidogrel, however, remains ineffective until the liver enzyme CYP2C19 metabolizes the drug into its active form. Some alternative medications, including ticagrelor, do not require activation through the same genetic pathway. Ticagrelor has its own risks, says Dr. Pereira, including serious or life-threatening bleeding. In addition, ticagrelor costs approximately six to eight times as much and must be taken twice a day, compared with clopidogrel.

MSS_0001451519 (2)

Dr. Chet Rihal

“Answering this question is important for the most appropriate and best patient care, and it also will help physicians and patients use health care dollars most responsibly,” says Chet Rihal, M.D., chair of cardiovascular services for Mayo Clinic and study chair.

About Mayo Clinic's Center for Individualized Medicine

The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. For more information, visit http://mayoresearch.mayo.edu/center-for-individualized-medicine/

Join us to learn more about precision medicine

Hear experts discuss how precision medicine can be applied to improve treatments for many conditions, including heart disease and cancer.

Attend Individualizing Medicine 2016: Advancing Care Through Genomics. Hosted by the Mayo Clinic Center for Individualized Medicine, the fifth annual genomics conference, October 5–6, in Rochester, Minn.

For a complete schedule and list of speakers, visit the conference website.  You may also learn more about the conference on the video blog series, “Story by Story.”   Follow the latest news related to the conference on the Center for Individualized Medicine blogFacebook or Twitter at @MayoClinicCIM and use the hashtag #CIMCon16.

The Mayo Clinic Center for Individualized Medicine is hosting the conference with support from the Satter Foundation.

Tags: #Antiplatlet Heart Medication, #Ticagrelor, angioplasty, Biomedical research, clopidogrel, Dr. Chet Rihal, Dr. Naveen Pereira, medical research, pharmacogenomics, Uncategorized

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy